Latest From NeurogesX Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.
Directly launching a drug in Europe is the most difficult path for US-based biopharma companies, many of which decide to out-license rights for that territory. But, for the right asset, it’s also the most rewarding. The authors review 11 years of EMA approvals to examine European entry strategies’ effects on company valuations.
Acorda Therapeutics paid NeurogesX $7.9 million up front for a commercial pain therapy and a late-stage, topical pain drug candidate – from which Acorda expects to derive the most value – as NeurogesX prepares to settle its debts and wind down its operations.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- NeurogesX Inc.
- Senior Management
Stephen F Ghiglieri, EVP, COO & CFO
Stephen J Peroutka, MD, PhD, EVP, CMO
- Contact Info
Phone: (650) 358-3300
999 Baker Way
San Mateo, CA 94404
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.